Coagulant’s CT-001 - An Opportunity To License A Novel Factor VIIa with Orphan Drug Designation for the Treatment of Severe Postpartum Hemorrhage (sPPH)

Our client, Coagulant Therapeutics Corporation (CTC), is developing a novel, patented (4 families due to expire 2041-2043 period) short-acting FVIIa (designated CT-001) for severe postpartum hemorrhage (sPPH), a significant and still largely unmet global clinical need in both developed and developing countries. CT-001 has recently received Orphan Drug Designation. We seek a partner for clinical development and commercialisation.

CT-001 with enhanced procoagulant activity was deliberately engineered in order to be short acting, the benefit of which is a significant reduction in thrombosis compared to the recombinant human FVIIa from Novo Nordisk (NovoSeven). CT-001 has also been shown to be more potent than Novo Nordisk’s FVIIa. Its safety and efficacy have been demonstrated in numerous relevant preclinical models. CT-001 has received FDA orphan designation for the treatment of sPPH.

CTC anticipates commencing a Phase 1 study in conjunction with a partner and is now seeking a global or regional partner to help develop  (in accordance with the key developmental milestones) and commercialize CT-001 as a 2nd line treatment for mothers with sPPH.

CTC estimates US peak sales to be ~$1 billion based on pricing equivalent to the procedural costs of UAE (Uterine Artery Embolization) ~$20,023. Based on the pricing of NovoSeven, the estimated peak sales is approximately $0.5 billion.

Please contact us for further information.